SCHEMBL2333867

SCHEMBL2333867

COCCN1C(=O)c2ccccc2C(C(=O)NCc2cccnc2)C1c1cccs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.58
TDP1 Q9NUW8 1/20 0.56
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.51
POLB P06746 1/20 0.51
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 4/20 0.48
KCNH2 Q12809 1/20 0.48
SCN5A Q14524 1/20 0.48
SCN9A Q15858 1/20 0.48
TSHR P16473 1/20 0.48
FPR1 P21462 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2331094 0.92 ALDH1A1 (0.54) HSD17B10TDP1ALDH1A1KDM4EMAPT
SCHEMBL2334153 0.91 ALDH1A1 (0.57) HSD17B10ALDH1A1KDM4EMAPTHTT
SCHEMBL2336986 0.87 CYP2C9 (0.49) HSD17B10TDP1ALDH1A1KDM4EMAPT
SCHEMBL2336637 0.86 L3MBTL1 (0.57) HSD17B10ALDH1A1KDM4EMAPTHTT
SCHEMBL2333920 0.86 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTHTTKMT2A
SCHEMBL2332851 0.85 ALDH1A1 (0.51) HSD17B10ALDH1A1KDM4EMAPTHTT
SCHEMBL2333958 0.84 ALDH1A1 (0.70) ALDH1A1KDM4EMAPTHTTCYP3A4
SCHEMBL14425766 0.84 HSD17B10 (0.56) HSD17B10TDP1ALDH1A1KDM4EMAPT
SCHEMBL2337628 0.83 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTHTTCYP2C9
SCHEMBL2334769 0.83 CYP2C9 (0.48) HSD17B10TDP1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP disclosed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 HSD17B10 1021/4885TDP1 3444/4885ALDH1A1 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.